t
| Date | 29 Apr 2022 |
| Time | 07:00:06 |
| Category | Results |
| ID | 8047J |
Annual Report and Financial Statements
PRESS RELEASE
29 April 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
FINAL RESULTS
Genflow (LSE: GENF) is pleased to announce its final results for the year ended 31 December 2021. The Annual Report is available to view on the Company's website at www.genflowbio.com
The Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.
Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
For further information please contact:
|
Genflow Biosciences Plc |
|
|
Dr Eric Leire Chief Executive |
via Tancredi +44 203 434 2330 |
|
Clear Capital Markets Ltd |
|
|
Corporate Broker Jonathan Critchley Keith Swann |
+44 203 869 6086 +44 203 897 0981 |
|
Tancredi Intelligent Communication Media Relations |
|
|
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio |
+44 7957 549 906 +44 7449 226 720 +44 7838 029 970 |
About Genflow
Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.
Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.
To learn more visit www.genflowbio.com
-Ends-